<DOC>
	<DOCNO>NCT00696904</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics ABT-333 healthy volunteer antiviral activity HCV infect subject .</brief_summary>
	<brief_title>Study ABT-333 Both Healthy Volunteers Hepatitis C Virus ( HCV ) + Genotype 1 Infected Subjects</brief_title>
	<detailed_description>Phase 1 , double-blind , randomize , placebo-controlled clinical trial healthy HCV genotype 1 infected adult evaluate safety , tolerability , antiviral activity pharmacokinetics ABT-333 .</detailed_description>
	<criteria>Main Selection Criteria Healthy Volunteers : Subject provide write consent . Subject general good health . If female , subject postmenopausal . If female , subject pregnant breastfeeding . Main Selection Criteria HCV+ Subjects : Subject HAVIgM , HBsAg HIV Ab negative . Subject HCV genotype 1 HCV RNA &gt; 50,000 IU/mL . Subject exclude previously receive antiviral therapy HCV infection Subjects must demonstrate chronic hepatitis C infection least 6 month prior study enrollment Subjects must prior liver biopsy histology consistent HCV induce liver damage , evidence cirrhosis liver pathology due cause chronic HCV . See main selection criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>